BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 12, 2009
 |  BC Week In Review  |  Company News  |  Other News

Facet Biotech cancer, autoimmune news

Facet restructured and reduced headcount by 78 (28%) to about 200 to reduce its operating costs. The company plans to narrow its focus to cancer but said its current programs will not be affected. Facet's pipeline includes daclizumab, a humanized mAb against IL-2...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >